Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Debt Ratio (2020 - 2025)

Gain Therapeutics has reported Debt Ratio over the past 6 years, most recently at 0.04 for Q3 2025.

  • Quarterly results put Debt Ratio at 0.04 for Q3 2025, up 12.38% from a year ago — trailing twelve months through Sep 2025 was 0.04 (up 12.38% YoY), and the annual figure for FY2024 was 0.04, up 18.53%.
  • Debt Ratio for Q3 2025 was 0.04 at Gain Therapeutics, down from 0.05 in the prior quarter.
  • Over the last five years, Debt Ratio for GANX hit a ceiling of 0.05 in Q2 2025 and a floor of 0.02 in Q1 2021.
  • Median Debt Ratio over the past 5 years was 0.03 (2023), compared with a mean of 0.03.
  • Biggest five-year swings in Debt Ratio: plummeted 76.83% in 2021 and later surged 86.83% in 2023.
  • Gain Therapeutics' Debt Ratio stood at 0.02 in 2021, then soared by 40.59% to 0.03 in 2022, then grew by 21.87% to 0.03 in 2023, then grew by 18.53% to 0.04 in 2024, then grew by 6.93% to 0.04 in 2025.
  • The last three reported values for Debt Ratio were 0.04 (Q3 2025), 0.05 (Q2 2025), and 0.04 (Q1 2025) per Business Quant data.